

Quality, safety and efficacy in a communication protocol between the anesthesiologist and the allergist in perioperative hypersensitivity reactions

Maria Anita Costa Spindola , Edelton Flavio Morato , Jane da Silva

PII: S0104-0014(21)00418-8
DOI: <https://doi.org/10.1016/j.bjane.2021.10.016>
Reference: BJANE 744340



To appear in: *Brazilian Journal of Anesthesiology (English edition)*

Received date: 18 June 2021
Accepted date: 24 October 2021

Please cite this article as: Maria Anita Costa Spindola , Edelton Flavio Morato , Jane da Silva , Quality, safety and efficacy in a communication protocol between the anesthesiologist and the allergist in perioperative hypersensitivity reactions, *Brazilian Journal of Anesthesiology (English edition)* (2021), doi: <https://doi.org/10.1016/j.bjane.2021.10.016>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Anestesiologia. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Quality, safety and efficacy in a communication protocol between the anesthesiologist and the allergist in perioperative hypersensitivity reactions

Maria Anita Costa Spindola^a, Edelson Flavio Morato^b, Jane da Silva^{c,*}
janedasilva1808@gmail.com

^aUniversidade Federal de Santa Catarina (HU-UFSC), Hospital Universitário Prof. Polydoro Ernani de São Thiago, Núcleo de Avaliação de Reação do Tipo Alérgico a Drogas (NARTAD), Florianópolis, SC, Brazil

^bUniversidade Federal de Santa Catarina (UFSC), Núcleo de Avaliação de Reação do Tipo Alérgico a Drogas (NARTAD), Departamento de Microbiologia, Imunologia e Parasitologia (MIP-UFSC), Florianópolis, SC, Brazil

^cUniversidade Federal de Santa Catarina (UFSC), Núcleo de Alergia e Núcleo de Avaliação de Reação do Tipo Alérgico a Drogas (NARTAD), Departamento de Clínica Médica, Florianópolis, SC, Brazil

***Corresponding author.**

Suspected hypersensitivity reactions in the perioperative period are unpredictable critical events with a potential risk of morbidity, such as neurological damage and mortality.[1] They pose a major challenge due to the various substances administered consecutively, hidden exposures, and associated clinical conditions that can make the clinical presentation difficult to recognize. Other clinical scenarios can mimic the presentation of hypersensitivity, whose confirmation is essential for safety in future exposures,[2] since it is impossible to determine clinically whether the reaction is immunological or not.[3] Correct investigation should guide appropriate management of future exposure of a patient.

Anesthesiologists are the professionals who most frequently witness hypersensitivity reactions during the perioperative period, diagnosing and treating the events, as well as collecting blood samples to measure mediators for diagnosis.

The interaction among anesthesiologists, allergists and immunologists, among others with extensive knowledge in drug allergy and perioperative anaphylaxis,[4] is warranted to

identify triggering agents as well as the reaction mechanism, in order to reduce the occurrence of re-exposure to triggering agents and, consequently, reduce morbidity and mortality and prevent perioperative anaphylaxis.

As in other organizations, the use of appropriate terminology among the teams involved is essential for successful management. Using a standardized vocabulary allows standardizing the data to be studied and minimizing missing information.

Thus, the proposal for a standardized instrument is presented in order to facilitate reporting of suspected perioperative allergy reactions, simplify communication among the professionals involved, help plan actions for diagnosis and guidance, and collect data for epidemiological studies.

An instrument for investigating perioperative hypersensitivity reaction was standardized (Fig. 1). The instrument consists of patient identification, admission data, place and time of reaction, substances used, description of the reaction, reaction management, outcome of the procedure, and test and investigation results.

The term hypersensitivity is comprehensive, as it encompasses reactions whose underlying mechanism may be allergic or non-allergic. It should be used to objectively describe reproducible symptoms or signs initiated by exposure to a defined stimulus at a dose tolerated by normal individuals.[3] This, therefore, is the appropriate term to describe a suspected clinical manifestation until the mechanism involved in the reaction is elucidated.[3] The World Allergy Organization (WAO), responsible for the revision of allergy nomenclature for global use, has recommended the standardization of terms.[5]

In convergence with the importance of nomenclature and correct classification of hypersensitivity events, not restricted to the perioperative period, the World Health Organization introduced the subsection on hypersensitivity to drugs, in its International Classification of Diseases, WHO ICD-11, aiming at more accuracy in the registration of events and collection of epidemiological data, which support better quality care and action planning.[6]

According to the current nomenclature, allergy is any hypersensitivity reaction triggered by a specific immune mechanism. Anaphylaxis, in turn, is defined as immediate onset of a systemic reaction, with life-threatening respiratory and circulatory impairment. There is also non-allergic hypersensitivity, which defines the clinical presentation resulting from non-specific

(direct) activation of cells of the immune system.[5] The modified Ring and Messmer scale is used to classify perioperative reactions clinically, according to the degree of intensity.[3]

In the investigation process of a perioperative reaction suspected of allergy, standardization in reporting can help minimize the risk of incomplete information and simplify communication among the professionals involved, helping to plan actions toward the correct diagnosis.

In a series of seventy patients assessed for perioperative hypersensitivity reaction, three of them had a new reaction on a subsequent exposure. In two of them, partial or incomplete information was the cause of inadvertent re-exposure to the causative agent; in the third, the cause was mastocytosis.[1]

In the investigation of suspected allergic reactions, an emerging challenge is the search for hidden agents administered by other routes of exposure that are not as clear. Antibiotics delivered by bone cement or surgical cement, methylene blue added to blood derivatives for viral inactivation are a few mentioned.[7] Recently, polyethylene glycols, which are widely used as excipients in medicinal products, including sprays of local anesthetics, cosmetics and household products, have been implicated as a suspected cause of anaphylaxis after the application of the mRNA COVID-19 vaccine.[9] Other possible agents rarely considered and that should deserve attention in the investigation are biological glues, hemostatic agents, irrigation fluids applied to the operative site, in addition to drug excipients and disinfectants.[7]

The less comprehensive version of the standardized instrument for investigating perioperative hypersensitivity reaction was presented at the World Allergy Conference.[9] It is a clinical practice-related protocol of the Núcleo de Avaliação de Reações do Tipo Alérgico a Drogas (NARTAD), in compliance with the recommendations established by services specializing in perioperative allergy investigation.[4] It corresponds to the norms established by the *Núcleo*, performing *in vivo* tests with neuromuscular blockers, antibiotics, opioids, Non-Steroid Analgesics (NSA), local anesthetics, latex and chlorhexidine. Skin tests are performed by prick test, and are intradermal; if indicated, challenge tests are also used. *In vitro* tests, such as specific measurement of IgE, tryptase, may also be requested as part of the investigation.

Anesthesiologists and allergists participated in the definition of information used to standardize perioperative hypersensitivity tests. The resulting final adjustments are presented in Figure 1.

The presentation of the instrument aims toward ample promotion and use among professionals involved in the investigation of suspected perioperative allergy events. Similar instruments are also used in other countries.[10]

Questions originated from the previously published standardized instrument[9] allowed the development of two questionnaires aimed at mapping events, their characteristics and diagnostic and therapeutic measures adopted. One questionnaire was distributed to Allergy specialists and another to Anesthesiology specialists, and answers are still to be evaluated. A third, more comprehensive and multicentric study, along with a national research network in Anesthesiology, is being prepared, and data collecting is anticipated for next year.

The communication protocol is expected to become simpler in order to report and send suspected perioperative hypersensitivity reactions for investigation, and, thus, move in the direction of the more widely recommended objective of preventing the risk event to occur. Moreover, we aim to promote a warning sign related to anaphylaxis and strengthen patient safety culture”.

Finally, we understand that employing a communication instrument between anesthesiologists and allergists to assess suspected perioperative or periprocedural hypersensitivity reactions during a period is a major step, in the cumbersome process of acknowledging, treating, diagnosing and preventing future reactions.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

We thank our colleague anesthesiologists and allergists who contributed with their reviews and suggestions to improve the present protocol.

References

1. Miller J, Clough SB, Pollard RC, Misbah SA. Outcomes of repeat anesthesia after investigation for perioperative allergy. *Br J Anaesth*. 2018;120:1195-201.
2. Melchior BLB, Garvey LH. Investigation of perioperative hypersensitivity reactions: an update. *Curr Opin Allergy Clin Immunol*. 2020;20:338-45.

3. Garvey LH, Ebo DG, Mertes PM, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. *Allergy*. 2019;74:1872-84.
4. Egner W, Cook T, Harper N, et al. Specialist perioperative allergy clinic services in the UK 2016: results from the Royal College of Anaesthetists Sixth National Audit Project. *Clin Exp Allergy*. 2017;47:1318-30.
5. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the nomenclature committee of the world allergy organization, October 2003. *J Allergy Clin Immunol*, 2004;113:832-36.
6. Tanno LK, Bierrenbach AL, Simons FER et al. Critical view of anaphylaxis epidemiology: open questions and new perspectives. *Allergy Asthma Clin Immunol*. 2018;14:12.
7. Garvey LH. Old, New and Hidden Causes of Perioperative Hypersensitivity. *Curr Pharm Des*. 2016; 22:6814-24.
8. Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? *Br J Anaesth*. 2021;126:e106-8.
9. Spindola MA, Da Silva J, Morato EF. Evaluation of perioperative hypersensitivity reactions: post-event interaction between anesthesiologist and allergist. *World Allergy Organ J*. 2015;8 Suppl 1:A143.
10. Laguna JJ, Archilla J, Doña I et al. Practical Guidelines for Perioperative Hypersensitivity Reactions. *J Investig Allergol Clin Immunol*. 2018;28:216-32.

Figure 1 Perioperative or periprocedural hypersensitivity reaction post-reaction assessment protocol.

PERIOPERATIVE HYPERSENSITIVITY REACTION INVESTIGATION PROTOCOL	
I- Patient Identification:	
Name: _____	
Date of Birth: ____ / ____ / ____ Tax ID#: _____ ID#: _____	
Address: _____	
City: _____ State: _____ ☐	
Phone: () _____	
Other contact: _____ Kinship: _____	
Phone: () _____	
SUS Card: _____	
Local Primary Care Health Center: _____	
Phone: () _____ Not applicable	
II - Hospital Admission Data	
Date of reaction: ____ / ____ / ____	
ASA: _____	
Comorbidity: _____	
Medication in use: _____	
History of medication allergy / History of other allergies: _____	
Yes No	
☐ Specify: _____	
Type of hospital admission: _____	
☐ Elective: _____ ☐ Outpatient: _____ ☐ Urgency _____ ☐ Emergency _____	
Surgery Proposed/Scheduled: _____	
III - Site / time of reaction:	
Anesthesia OR:	
☐ Induction ☐	
☐ Maintenance ☐	
☐ Reversal/End	
☐ PACU**	
Radiologic exam _____	
ICU _____	
Others: _____	
IV - Substances used (Check agent and fill out name of medication/substance used):	
Induction agents: _____	
☐ Opioids: _____	
☐ Neuromuscular blockers: _____	
☐ Local anesthetics: _____	
☐ Regional block adjuvants: _____	
IV-Continued	
☐ Non-steroid anti-inflammatory drugs (NSAID): _____	
☐ Radiology contrasts: _____	
☐ Antibiotics: _____	
☐ Dyes: _____	
☐ Analgesics: _____	
☐ Blood and blood products: _____	
☐ Antifibrinolytics: _____	
☐ Latex ☐ Povidone-iodine ☐ Chlorhexidine	
Others: _____	
IV b - Surgical field materials/substances used: Implants / Orthoses (e.g.: implantable pacemaker, cochlear implant, intraocular lens)	
☐ Bone cement	
☐ Irrigation solutions	
☐ Biological glues	
☐ Hemostatic agents	
☐ Pads/surgical sponges embedded in antiseptics	
Others: _____	
IV c - Other exposures:	
☐ Spray	
☐ Gel	
☐ embedded/coated catheters	
☐ Laryngoscopes immersed in chlorhexidine	
☐ OPA*** or GLU**** material disinfectants	
Others: _____	

V – Reaction data:

Was there a time relationship between exposure to any substance and symptom/sign onset?

☐ Yes Describe: _____
☐ No

Time surgery initiated: _____

Time reaction initiated: _____

Signs and symptoms observed (List in chronological order):

- ☐ Erythema
☐ Pruritus
☐ Urticaria
☐ Angioedema
☐ Airway pressure increase
☐ Bronchospasm
☐ Cyanosis/O₂ Desaturation (minimum saturation value_%)
☐ Tachycardia
☐ Bradycardia
☐ Arrhythmias
☐ Hypotension (minimum value observed_mmHg)
☐ Cardiorespiratory arrest

Others: _____

According to the classification, what is the level of severity of the reaction presented by the patient?
 Modified Ringe Messmer classification³ (Severity Scale for immediate hypersensitivity reactions):

- ☐ **Grade I** – Skin symptoms: Generalized erythema, urticaria, **angioedema**
- ☐ **Grade II** – Detectable symptoms but not life-threatening: skin signs, hypotension, tachycardia, cough, breathing difficulties
- ☐ **Grade III** – Life-threatening symptoms: Circulatory collapse, tachycardia or bradycardia, arrhythmias, bronchospasm
- ☐ **Grade IV** – Cardiorespiratory arrest

VI – Reaction management:

Treatment provided (by chronological order):

- ☐ Trendelenburg Position
☐ IV Fluids
☐ Oxygen
☐ ETT required
☐ Already intubated
☐ Mask
☐ Epinephrine
 Route: ☐ IM Dose: _____
 Route: ☐ IV Dose: _____
 Route: ☐ another Dose: _____

☐ Vasopressor? Specify: _____

- ☐ Glucagon
☐ Corticoids
☐ Anti-histaminic
 Others: _____

Blood sample to determine tryptase:

- ☐ up to 2 hours after reaction
☐ 2 – 4 hours after
☐ 24 hours
☐ Not performed

VII Procedure outcome

- ☐ Abbreviated surgery
☐ Surgery concluded as scheduled
☐ Surgery cancelled for:

Patient follow up / recovery at:

- ☐ SRPA
☐ Inpatient Unit
☐ ICU: ☐ Ventilatory Support
☐ Vasoactive drugs

Inpatient Stay:

- ☐ Unit days: _____
☐ ICU days: _____

- ☐ Deceased Time of occurrence:
☐ During treatment of reaction
☐ Up to 24h after reaction
☐ 24-48 h after reaction
☐ 48 h after reaction

VIII – From allergist:☐ Not applicable

Test results:

IN VIVO (specify): _____

IN VITRO (specify): _____

Challenge test: Yes ☐ No ☐

Specify: _____

The following agents:

- Ethylene oxide: ☐ Yes ☐ No
 - PEG: ☐ Yes ☐ No
 - Other excipients: ☐ Yes ☐ No

Which one: _____

Were they tested? ☐ Yes ☐ NoWere they excluded as cause of reaction? ☐ Yes ☐ No☐ Not applicable**VIII b - Results of Investigation:**☐ Inconclusive tests, requiring further investigationWas an IgE-dependent reaction identified? ☐ Yes ☐ No

Final Diagnosis: _____

- Drugs to be avoided until further investigation: _____

- Drugs to be absolutely avoided: _____

Obs: In case of tests positive to Neuromuscular Blockers (NMB), use only agents with negative result tests. New NMB introduced into practice, should be tested before using, due to N high MB cross-reactivity.

Joint discussion allergist / anesthetist:

☐ Performed☐ Unnecessary☐ Necessary, but not performed

Report sent to:

☐ Anesthetist

CRM: _____

☐ Surgeon

CRM: _____

☐ Allergist

CRM: _____

Others: _____

Reported to hospital pharmacovigilance?

☐ Yes☐ No

Reported to National Regulatory Agency?

☐ Yes☐ No

CRM license number of the physician reporting the reaction: _____

CRM=Regional Medical Council

Legend:

*ASA: American Society of Anesthesiology
(Physical Status Classification)
**PACU: Post-Anesthesia Care Unit

***OPA: orthophthalaldehyde
****GLU: glutaraldehyde
*****PEG: polyethylene glycol